The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines: a retrospective study

Human epidermal growth factor receptor 2 (HER-2) is the prognostic and predictive biomarker for breast cancer found in a quarter of all breast cancer cases. Precise testing of HER-2 will impact treatment response.Based on the updated American Society of Clinical Oncology/College of American Patholog...

Descripción completa

Detalles Bibliográficos
Autor principal: Thambamroong, Tawasapon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116994/
https://www.ncbi.nlm.nih.gov/pubmed/35702411
http://dx.doi.org/10.3332/ecancer.2022.1370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116994/
https://www.ncbi.nlm.nih.gov/pubmed/35702411
http://dx.doi.org/10.3332/ecancer.2022.1370

Ejemplares similares